GlassScriptPhysician profile
Sean R Kark
NPI 1588025589
$3,676.29
in general payments reported to CMS, 2019-2025
28 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2021: $131 · 2022: $125 · 2023: $558 · 2024: $718 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.12 | 2021-2025 | Airsupra, Breztri, Nexium |
| Abbvie INC. | $479.42 | 2019-2025 | |
| Pfizer INC. | $392.90 | 2023-2025 | |
| Novo Nordisk INC | $250.52 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $249.41 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $167.90 | 2024-2025 | |
| Ethicon INC. | $133.65 | 2025 | Monarch Platform |
| Lilly USA, LLC | $126.70 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Idorsia Pharmaceuticals US INC | $124.80 | 2023 | Quviviq |
| Biogen, INC. | $122.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $84.60 | 2019-2025 | Eterna |
| Amgen INC. | $79.28 | 2023-2025 | Repatha, Otezla, Repatha |
| Intercept Pharmaceuticals, INC. | $73.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.70 | 2023-2024 | Spravato |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.54 | 2021-2024 | Gardasil 9, Vaxelis, Gardasil |
| Astellas Pharma US INC | $61.32 | 2024-2025 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $39.15 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $33.86 | 2024 | Gemtesa |
| Vanda Pharmaceuticals INC. | $28.09 | 2025 | Fanapt |
| Hologic Sales and Service, LLC | $26.42 | 2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $24.10 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.09 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $23.23 | 2024 | |
| Boston Scientific Corporation | $21.28 | 2025 | General - Pain Management |
| Dexcom, INC. | $21.02 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $19.28 | 2025 | Fluad, Flucelvax |
| Exeltis, USA INC. | $16.21 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Kark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.